AbbVie Inc. · News & developments
Allergan Aesthetics Tests Skincare Regimens on Weight-Loss Patients in Pilot Studies
Allergan Aesthetics released findings from two small single-center clinical studies at the Science of Skin Summit assessing topical skincare regimens and DiamondGlow dermabrasion in patients on medical weight-loss drugs. In a 12-week study with nine completers, investigator-assessed skin quality improvements appeared as early as week two, and subjects reported facial skin appearing roughly 10 years younger after four weeks of serum use. The 12-week skincare study included nine participants who completed the study, while the six-week DiamondGlow plus skincare study included 11 participants who completed at least one post-treatment assessment.
Why this matters
Rapid medical weight loss from GLP-1 therapies often triggers loss of facial volume and skin sagging, opening an addressable adjunctive market. Allergan Aesthetics is attempting to build clinical backing for its out-of-pocket, cash-pay topical products and in-office exfoliation devices. However, trial cohorts of nine and eleven participants represent exploratory pilots rather than definitive evidence; investors should treat commercial adoption projections as unproven until replicated in broader patient registries.